Polygenic and transcriptional risk scores identify chronic obstructive pulmonary disease subtypes

Matthew Moll,Julian Hecker,John Platig,Auyon J. Ghosh,Rui-Sheng Wang,Katherine Pratte,Davin Hill,Iain Konigsberg,Joe W. Chiles III,Craig P. Hersh,Peter J. Castaldi,Kimberly Glass,Jennifer G. Dy,Jingzhou Zhang,Don D. Sin,Ruth Tal-Singer,Majd Mouded,Stephen I. Rennard,Gary Anderson,Gregory L Kinney,Russell Bowler,Jeffrey L. Curtis,Merry-Lynn McDonald,Edwin K. Silverman,Brian D. Hobbs,Michael H. Cho

DOI: https://doi.org/10.1101/2024.05.20.24307621

2024-05-21

Abstract:Rationale: Genetic variants and gene expression predict risk of chronic obstructive pulmonary disease (COPD), but their effect on COPD heterogeneity is unclear. Objectives: Define high-risk COPD subtypes using both genetics (polygenic risk score, PRS) and blood gene expression (transcriptional risk score, TRS) and assess differences in clinical and molecular characteristics. Methods: We defined high-risk groups based on PRS and TRS quantiles by maximizing differences in protein biomarkers in a COPDGene training set and identified these groups in COPDGene and ECLIPSE test sets. We tested multivariable associations of subgroups with clinical outcomes and compared protein-protein interaction networks and drug repurposing analyses between high-risk groups. Measurements and Main Results: We examined two high-risk omics-defined groups in non-overlapping test sets (n=1,133 NHW COPDGene, n=299 African American (AA) COPDGene, n=468 ECLIPSE). We defined 'High activity' (low PRS/high TRS) and 'severe risk' (high PRS/high TRS) subgroups. Participants in both subgroups had lower body-mass index (BMI), lower lung function, and alterations in metabolic, growth, and immune signaling processes compared to a low-risk (low PRS, low TRS) reference subgroup. 'High activity' but not 'severe risk' participants had greater prospective FEV1 decline (COPDGene: -51 mL/year; ECLIPSE: -40 mL/year) and their proteomic profiles were enriched in gene sets perturbed by treatment with 5-lipoxygenase inhibitors and angiotensin-converting enzyme (ACE) inhibitors. Conclusions: Concomitant use of polygenic and transcriptional risk scores identified clinical and molecular heterogeneity amongst high-risk individuals. Proteomic and drug repurposing analysis identified subtype-specific enrichment for therapies and suggest prior drug repurposing failures may be explained by patient selection.